Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
44.43
+0.08 (0.18%)
At close: Nov 19, 2025, 4:00 PM EST
45.27
+0.84 (1.89%)
Pre-market: Nov 20, 2025, 8:47 AM EST
Qiagen Market Cap
Qiagen has a market cap or net worth of $9.63 billion as of November 20, 2025. Its market cap has decreased by -0.12% in one year.
Market Cap
9.63B
Enterprise Value
10.10B
1-Year Change
-0.12%
Ranking
Category
Stock Price
$44.43
Market Cap Chart
Since December 1, 1998, Qiagen's market cap has increased from $1.78B to $9.63B, an increase of 441.04%. That is a compound annual growth rate of 6.46%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 18, 2025 | 9.65B | -3.17% |
| Dec 31, 2024 | 9.97B | 0.61% |
| Dec 29, 2023 | 9.91B | -12.73% |
| Dec 30, 2022 | 11.36B | -10.13% |
| Dec 31, 2021 | 12.64B | 3.57% |
| Dec 31, 2020 | 12.20B | 60.05% |
| Dec 31, 2019 | 7.62B | -2.34% |
| Dec 31, 2018 | 7.80B | 7.58% |
| Dec 29, 2017 | 7.26B | 11.12% |
| Dec 30, 2016 | 6.53B | 1.77% |
| Dec 31, 2015 | 6.42B | 16.92% |
| Dec 31, 2014 | 5.49B | -1.74% |
| Dec 31, 2013 | 5.58B | 31.36% |
| Dec 31, 2012 | 4.25B | 32.05% |
| Dec 30, 2011 | 3.22B | -29.04% |
| Dec 31, 2010 | 4.54B | 2.70% |
| Dec 31, 2009 | 4.42B | 28.80% |
| Dec 31, 2008 | 3.43B | 8.51% |
| Dec 31, 2007 | 3.16B | 40.73% |
| Dec 29, 2006 | 2.25B | 30.03% |
| Dec 30, 2005 | 1.73B | 7.89% |
| Dec 31, 2004 | 1.60B | -8.01% |
| Dec 31, 2003 | 1.74B | 133.79% |
| Dec 31, 2002 | 744.50M | -72.04% |
| Dec 31, 2001 | 2.66B | 49.20% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 939.79B |
| Johnson & Johnson | 487.91B |
| AbbVie | 411.64B |
| UnitedHealth Group | 279.99B |
| AstraZeneca | 275.69B |
| Novartis AG | 244.75B |
| Merck & Co. | 235.92B |
| Abbott Laboratories | 219.36B |